Target type: biologicalprocess
Any process that decreases the rate, frequency or extent of plasminogen activation. Plasminogen activation is the process in which plasminogen is processed to plasmin. [GOC:BHF, GOC:dph, GOC:tb]
Negative regulation of plasminogen activation is a crucial biological process that controls the conversion of plasminogen to plasmin, a potent serine protease involved in various physiological processes, including fibrinolysis, wound healing, and tissue remodeling. Plasminogen activation is tightly regulated to prevent uncontrolled proteolysis and tissue damage. The primary mechanism involves the inhibition of the key enzyme responsible for plasminogen activation, tissue plasminogen activator (tPA). This inhibition can occur through multiple pathways:
1. **Inhibition of tPA activity:**
- **Plasminogen activator inhibitor-1 (PAI-1):** PAI-1 is the primary inhibitor of tPA in circulation and tissues. It binds to tPA and forms a stable complex that prevents tPA from activating plasminogen.
- **α2-antiplasmin:** This protein is a fast-acting inhibitor of plasmin, effectively preventing its proteolytic activity. It can also indirectly inhibit tPA by binding to plasmin, preventing it from activating more plasminogen.
- **Thrombin-activatable fibrinolysis inhibitor (TAFI):** TAFI is a carboxypeptidase that cleaves lysine residues from fibrin, decreasing the affinity of tPA for fibrin. This reduces the efficiency of tPA in activating plasminogen bound to fibrin.
2. **Regulation of tPA expression and release:**
- **Cytokines and growth factors:** Factors like TNF-α, IL-1β, and TGF-β can suppress tPA production in various cell types.
- **Hormones:** Estrogens promote PAI-1 production, leading to reduced tPA activity.
- **Cellular signaling pathways:** Multiple intracellular signaling pathways, including the MAPK and PI3K pathways, can regulate tPA expression and release.
3. **Removal of tPA from circulation:**
- **Liver clearance:** tPA is cleared from circulation mainly by the liver.
The intricate interplay of these regulatory mechanisms ensures that plasminogen activation occurs only when and where it is required, preventing excessive fibrinolysis and maintaining tissue integrity. Dysregulation of negative regulation of plasminogen activation can lead to pathological conditions such as thrombosis, bleeding disorders, and cancer progression.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cathepsin Z | A cathepsin Z that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UBR2] | Homo sapiens (human) |
Carboxypeptidase B2 | A carboxypeptidase B2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q96IY4] | Homo sapiens (human) |
Plasminogen activator inhibitor 1 | A plasminogen activator inhibitor 1 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P05121] | Homo sapiens (human) |
Tissue-type plasminogen activator | A tissue-type plasminogen activator that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00750] | Homo sapiens (human) |
Urokinase-type plasminogen activator | A urokinase-type plasminogen activator that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00749] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
gallic acid | gallate : A trihydroxybenzoate that is the conjugate base of gallic acid. | trihydroxybenzoic acid | antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite |
4-aminobenzamidine | 4-aminobenzamidine: a urokinase inhibitor; inhibits acrosin; structure given in first source | ||
4-iodine-benzo(b)thiophene-2-carboxamidine | |||
5-(n,n-hexamethylene)amiloride | 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring. 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity | aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines | antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker |
benzamidine | benzamidine : A carboxamidine that is benzene carrying an amidino group. benzamidine: RN given refers to parent cpd | benzenes; carboxamidine | serine protease inhibitor |
bis(5-amidino-2-benzimidazolyl)methane | bis(5-amidino-2-benzimidazolyl)methane: aromatic diamidine which has a significant suppressive effect on the cytopathology & yield of respiratory synctial (RS) virus; RN given refers to parent cpd | ||
gabexate | Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin. | benzoate ester | |
hexachlorophene | hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union. Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797) | bridged diphenyl fungicide; polyphenol; trichlorobenzene | acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug |
benzylsuccinic acid | 2-benzylsuccinic acid : A dicarboxylic acid consisting of succinic acid carrying a 2-benzyl substituent. benzylsuccinic acid: inhibitor of carboxypeptidase A | dicarboxylic acid | bacterial xenobiotic metabolite |
netropsin | Netropsin: A basic polypeptide isolated from Streptomyces netropsis. It is cytotoxic and its strong, specific binding to A-T areas of DNA is useful to genetics research. | ||
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2. | aromatic ether; C-nitro compound; sulfonamide | antineoplastic agent; cyclooxygenase 2 inhibitor |
pentamidine | pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease. Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | aromatic ether; carboxamidine; diether | anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic |
1,2,5,8-tetrahydroxy anthraquinone | 1,2,5,8-tetrahydroxy anthraquinone: structure in first source quinalizarin : A tetrahydroxyanthraquinone having the four hydroxy groups at the 1-, 2-, 5- and 8-positions. | tetrahydroxyanthraquinone | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor |
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
tranexamic acid | Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage. | amino acid | |
dibrompropamidine | aromatic ether | ||
2-aminobenzimidazole | 2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group. 2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd | benzimidazoles | marine xenobiotic metabolite |
phenylguanidine | phenylguanidine: RN given refers to parent cpd | ||
amiloride | amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid. Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) | aromatic amine; guanidines; organochlorine compound; pyrazines | diuretic; sodium channel blocker |
2-aminotetralin | 2-aminotetralin: RN given refers to parent cpd without isomeric designation; structure | tetralins | |
epigallocatechin gallate | (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis) | flavans; gallate ester; polyphenol | antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite |
hexamidine | hexamidine : A polyether that is the bis(4-guanidinophenyl) ether of hexane-1,6-diol. | aromatic ether; guanidines; polyether | antimicrobial agent; antiseptic drug |
amiloride hydrochloride | amiloride hydrochloride dihydrate : A hydrate that is the dihydrate of amiloride hydrochloride. | hydrate | diuretic; sodium channel blocker |
sennoside A | sennoside A : A member of the class of sennosides that is rel-(9R,9'R)-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid which is substituted by hydroxy groups at positions 4 and 4', by beta-D-glucopyranosyloxy groups at positions 5 and 5', and by oxo groups at positions 10 and 10'. The exact stereochemisty at positions 9 and 9' is not known - it may be R,R (as shown) or S,S. | oxo dicarboxylic acid; sennosides | |
1-aminoisoquinoline | |||
mci 9038 | peptide | ||
sivelestat | sivelestat: inhibitor of neutrophil elastase; structure given in first source | N-acylglycine; pivalate ester | |
dx 9065 | |||
efegatran | efegatran: RN & structure given in first source; RN given refers to parent cpd (D)-isomer | ||
5-amidinoindole | |||
4-guanidinobenzoate | 4-guanidinobenzoate: RN given refers to parent cpd 4-guanidinobenzoic acid : Benzoic acid substituted at the para position by a guanidino group. | benzoic acids; guanidines | |
melagatran | azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound | anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor | |
beta-naphthamidine | beta-naphthamidine: RN given refers to parent cpd | ||
sq 24798 | 2-mercaptomethyl-5-guanidinopentanoic acid: structure | ||
3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine | 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine: amiloride prodrug; structure given in first source | ||
7-amino-3-(2-bromoethoxy)-4-chloroisocoumarin | 7-amino-3-(2-bromoethoxy)-4-chloroisocoumarin: RN & structure given in first source | ||
razaxaban | razaxaban: structure in first source | ||
dabigatran | dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. | aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines | anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor |
actinonin | actinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure | ||
benzamidine | carboxamidinium ion | ||
Epigallocatechin 3,5-Digallate | catechin | ||
2-(4-chlorophenyl)guanidine | organochlorine compound | ||
7-amino-4-chloro-3-(3-isothiureidopropoxy)isocoumarin | 7-amino-4-chloro-3-(3-isothiureidopropoxy)isocoumarin: structure given in first source | ||
silybin | |||
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
rutin | quercetin-3-O-rutinoside: structure in first source | flavonoids; glycoside | |
pai 039 | tiplaxtinin: inhibitor of plasminogen activator inhibitor-1 | indole-3-acetic acids | |
bms 740808 | 1-(3-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-6-(2'-(3-hydroxy-N-pyrrolidinyl)methyl-(1,1')-biphen-4-yl)-1,4,5,6-tetrahydropyrazolo-(3,4-c)-pyridin-7-one: structure in first source | ||
xr 334 | XR 334: a low molecular weight modulator of human plasminogen activator inhibitor-1 activity; structure given in first source; RN given refers to (Z,Z)-isomer | ||
b 428 | 4-iodine-benzo(b)thiophene-2-carboxamidine: structure in first source | ||
bms-262084 | BMS-262084: an azetidinone-based tryptase inhibitor; structure in first source | ||
upamostat | |||
uk-356,202 | UK-356,202: structure in first source | ||
n-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(l)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride | |||
dpc 423 | |||
gw 813893 | |||
lb 30057 | |||
odanacatib | odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source | ||
a-317567 | A-317567: acid sensing ion channel blocker; structure in first source | ||
betrixaban | betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade. betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source | benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide | anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor |
ko 143 | beta-carbolines; tert-butyl ester | ||
rpr 120844 | |||
m-chlorophenylguanidine | |||
sideroxylonal c | sideroxylonal C: formylated phloroglucinol from flowers of Eucalyptus albens; structure in first source | ||
anabaenopeptin b | anabaenopeptin B: from cyanobacteria Planktothrix (Oscillatoria) rubescens | ||
pf-429242 | PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
6-(3,5-difluoroanilino)-9-(2,2-difluoroethyl)-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
rpx7009 | RPX7009: a beta-lactamase inhibitor; structure in first source |